Full Text:
<776>
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2022-10-13
Cited: 0
Clicked: 756
Cancer immunotherapy: an evolving paradigm
| ||||||||||||||
Aifu LIN. Cancer immunotherapy: an evolving paradigm[J]. Journal of Zhejiang University Science B, 2022, 23(10): 791-792.
@article{title="Cancer immunotherapy: an evolving paradigm",
author="Aifu LIN",
journal="Journal of Zhejiang University Science B",
volume="23",
number="10",
pages="791-792",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2210001"
}
%0 Journal Article
%T Cancer immunotherapy: an evolving paradigm
%A Aifu LIN
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 10
%P 791-792
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2210001
TY - JOUR
T1 - Cancer immunotherapy: an evolving paradigm
A1 - Aifu LIN
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 10
SP - 791
EP - 792
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2210001
[1]ChenJ, ChenJ, WangL, 2022. Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor infiltrating immunocytes. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):812-822.
[2]FangL, QiH, WangP, et al., 2022. UPF1 increases amino acid levels and promotes cell proliferation in lung adenocarcinoma via the eIF2α-ATF4 axis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):863-875.
[3]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.
[4]GuTN, ZhuM, HuangH, et al., 2022. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):793-811.
[5]KongDL, YangTT, GengJ, et al., 2022. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):876-880.
[6]QuL, HeXY, TangQ, et al., 2022. Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):844-862.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>